We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Critique |

A Strong Argument for Improving Access Without Delay Comment on “Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/Ethnicity”

Leigh Neumayer, MD, MS
JAMA Surg. 2013;148(6):524. doi:10.1001/jamasurg.2013.1691.
Text Size: A A A
Published online


In this analysis of a large database, Smith et al1 explore the influence of delay in initiation of treatment for AYA women with breast cancer. Using the California Cancer Registry, Smith et al were able to determine time between diagnosis and initiation of treatment, whether that be surgery or chemotherapy. While difficult to sort out when so much information is presented as in this article, it was only a small subset of patients (those who got surgery only) in which the treatment delay (time from diagnosis to treatment of greater than 6 weeks) was associated in multivariate analysis with decreased survival (adjusted HR, 1.82; 95% CI, 1.21-2.74). Patients who received chemotherapy as part of their treatment were not found to have an independent association between treatment delay and survival. To provide further perspective, adjusted HRs for likelihood of death by cancer stage ranged from 3.14 for stage II to 24.51 for stage IV. Also, interestingly, race was an important predictor of survival for those who received chemotherapy in addition to surgery but not for those who received surgery only.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Users' Guides to the Medical Literature
Are the results credible?

Users' Guides to the Medical Literature
Was Data Collection Sufficiently Comprehensive and Detailed?